Search Results

Axogen, Inc. announces the launch of its newest product, Avive+ Soft Tissue Matrix™. Avive+™ is intended for use as a soft tissue barrier and is a resorbable, multi-layer amniotic membrane allograft that provides temporary protection and tissue separation during the critical phase of peripheral nerve healing.

FibroBiologics, Inc. announced that Chief Scientific Officer, Hamid Khoja, Ph.D., will present on FibroBiologics’ wound care and psoriasis programs at the Extracellular Matrix (ECM) Pharmacology Congress in Copenhagen, Denmark, from June 17-19, 2024.

Crucial Data Solutions (CDS), the only SaaS platform provider to empower customer-driven global clinical trials for web and mobile environments, announced today they have been recognized as a Major Contender in Everest Group’s Decentralized Clinical Trial Platforms PEAK Matrix® for the second year in a row.

Adlai Nortye Ltd. (NASDAQ: ANL) (the “Company” or “Adlai Nortye”) today announced that it will present encouraging preliminary data of AN0025 in combination with definitive chemoradiotherapy (dCRT) in unresectable locally advanced or locally recurrent esophageal cancer (EC) at the upcoming American Society of Cancer Oncology (ASCO) Annual Meeting to be held in Chicago from May 31 to June 4, 2024.

Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, announces the first surgical implantations of its newest product, Avive+ Soft Tissue Matrix™.

Omeza®, a regenerative skincare company that develops marine-based therapies for wounds that are hard to treat, announced completion of a multi-center clinical study which evaluated OCM™ Wound Matrix in the treatment of a variety of chronic non-healing wounds/ulcers.